Stephen Schuster, MD, Gives Advice for Treating Aggressive Lymphomas During COVID-19 Pandemic

Article

Stephen Schuster, MD, talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently.

Stephen Schuster, MD, of Penn Medicine talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently.

Transcription:

As I said, some of our visits that are very routine can be done remotely. That actually saves time, number 1, and it also reduces traffic to the cancer center and through the waiting room and into the exam room. I think if we can continue to maintain that, we’ll have greater capacity to see patients that need to be seen. People that are being evaluated up front with either a new diagnosis or for evaluation for CAR T, we’ll be able to bring more patients in because our schedule won’t be quite as cluttered with routine follows up, which we can still do, but we can do more efficiently and remotely. We’ll have more space in clinic, more space in our schedules, and probably be able to handle a greater volume of patients.

Recent Videos
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
Related Content